Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gram Negative and Positive clinical Isolates

ABSTRACT: Study of Antimicrobial resistance of Clinical Isolates

PROVIDER: PRJNA863411 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gram-negative isolates

Project description:Gram-negative clinical isolates from LMIC

| PRJNA1322038 | ENA

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

Project description:The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization mass spectrometry (A-MALDI) method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 KPC, 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/4; OXA-48 or OXA-181 or OXA-232; GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC & NDM; KPC & OXA; KPC & GES; NDM & OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase’s subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health.

2024-11-26 | PXD058284 | Pride

Universal antimicrobial resistance detection from clinical bacterial isolates using proteomics

Project description:Universal antimicrobial resistance detection from clinical bacterial isolates using proteomics

| PRJEB39816 | ENA

Clinical isolates sequencing

Project description:Clinical isolates sequencing

| PRJNA627194 | ENA

Clinical isolates sequencing

Project description:Clinical isolates sequencing

| PRJNA754843 | ENA

Mtb clinical isolates

Project description:Mtb clinical isolates